Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA, SDK002, Chemotherapy, and Tislelizumab in Advanced Pancreatic Cancer
NCT07348107Phase 1Not yet recruiting
- Sponsor
- Daniel Breadner
- Start
- Feb 2026
- Primary completion
- Mar 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tretinoin and arsenic trioxide in pancreatic ductal adenocarcinoma (PDAC), sponsored by Daniel Breadner. Primary endpoint: Number of Participants with Adverse Events as Assessed by CTCAE v5.0 at 6 months. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
tretinoinarsenic trioxide
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07348107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07348107.